From Proteopedia
proteopedia linkproteopedia link Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1]
|
| Parameter
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Tmax (hr)
| 4
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Cmax (ng/ml)
| 115
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Bioavailability (%)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Protein Binding (%)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| T1/2 (hr)
| 9.6
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| AUC (ng/ml/hr)
| 1429
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| IC50 (nM)
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Dosage (mg)
| 100
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
| Metabolism
| Lapatinib (Tykerb)
| Sunitinib (Sutent)
| Sorafenib (Nexavar)
|
- ↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
